Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.56 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.53 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3613601 | 0.87 | SLC2A2 (0.69) | ALDH1A1KDM4EHPGDHSD17B10CYP1A2 | |
| SCHEMBL22780401 | 0.85 | NTRK1 (0.57) | ALDH1A1KDM4EPKMHPGDHSD17B10 | |
| SCHEMBL13341887 | 0.85 | SMN1; SMN2 (0.56) | ALDH1A1KDM4EPKMHPGDHSD17B10 | |
| SCHEMBL6686729 | 0.84 | NTRK1 (0.58) | ALDH1A1KDM4EPKMHPGDHSD17B10 | |
| SCHEMBL7096969 | 0.82 | NTRK1 (0.56) | ALDH1A1KDM4EPKMHPGDHSD17B10 | |
| SCHEMBL13341895 | 0.82 | NPC1 (0.56) | ALDH1A1KDM4EPKMHPGDHSD17B10 | |
| SCHEMBL13341897 | 0.81 | GABRB2 (0.62) | ALDH1A1KDM4EHPGDHSD17B10CYP1A2 | |
| SCHEMBL22780031 | 0.81 | GAA (0.71) | ALDH1A1KDM4EPKMHPGDHSD17B10 | |
| SCHEMBL2937274 | 0.79 | DPP4 (0.50) | ALDH1A1KDM4EPKMHPGDHSD17B10 | |
| SCHEMBL1430614 | 0.78 | SLC2A2 (0.77) | ALDH1A1KDM4EHPGDHSD17B10CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980887-B2 | 2-aryl imidazo[1,2-a]pyridine-3-acetamide derivatives, preparation methods and uses thereof | INSTITUTE OF PHARMACOLOGY (CN) | 2015-03-17 | — | — | US | disclosed |
| US-20130203754-A1 | 2-Aryl Imidazo[1,2-a]Pyridine-3-Acetamide Derivatives, Preparation Methods and Uses Thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2013-08-08 | — | — | US | disclosed |
| US-7723324-B2 | Imidazo[1,2-A]pyridine anxiolytics | SEPRACOR, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7566725-B2 | Imidazo[1,2-A] pyridine anxiolytics | SEPRACOR INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20080096867-A1 | Imidazo[1,2-A] Pyridine Anxiolytics | SEPRACOR INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20070043074-A1 | IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS | SEPRACOR INC. (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043074-A1 | IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS | CNR1, CNR2, GABRA5 | ALDH1A1 300/4885KDM4E 995/4885PKM 906/4885 |
| US-20130203754-A1 | 2-Aryl Imidazo[1,2-a]Pyridine-3-Acetamide Derivatives, Preparation Methods and Uses Thereof | TSPO, SLC6A1, TBXA2R | ALDH1A1 680/4885KDM4E 3821/4885PKM 759/4885 |
| US-20080096867-A1 | Imidazo[1,2-A] Pyridine Anxiolytics | MTNR1B, ADORA2B, ADRA2B | ALDH1A1 321/4885KDM4E 796/4885PKM 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.